As part of the agreement, Catalent will engineer a cell line expressing Nascent’s Pritumumab antibody using Catalent’s GPEx technology.
Catalent will produce purified monoclonal antibody to support Nascent’s Phase I/II human clinical trials with Pritumumab for treatment of brain cancers, such as astrocytomas and glioblastomas.
Nascent CEO Mark Glassy said: "Nascent Biologics is in the process of forming a commercial partnership for further clinical development, registration, and marketing of its Pritumumab product."